Patient P-02039
Therapy response
Unstable
Tolerance
Unstable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 65 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 81 GI-04 recommended — GI Support Protocol GI-04
- Day 82 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 65.
Primary contributors, last 14 days
- GI instability+17
- Inflammatory activity+10
- Nutritional resilience-8
- Toxicity+7
- Treatment adherence-4
What helped?
- GI Support Protocol GI-04Day 81Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 89% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 64 and rising
- WearableSleep 5.4 h, below personal baseline
- Autonomic recovery ↓65
- WearableResting HR 79 bpm
- Wearable300 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 62
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 31/100
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑25
- BloodInflammatory load index 66
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 1.9 · butyrate capacity 31/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 39 ms
- Sleep
- 5.4 h
- Steps
- 463
- Resting HR
- 77 bpm
Daily log: GI score 64, nutritional resilience 37, adherence 40.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02018 | 38% | S01 | GI-04 | improved | 46 |
| P-02410 | 32% | S01 | GI-04 | improved | 55 |
| P-02409 | 31% | S01 | SC-12 | no change | 54 |
| P-02054 | 28% | S01 | CR-01 | improved | 57 |
| P-02307 | 18% | S01 | — | — | 55 |
| P-02598 | 18% | S01 | — | — | 53 |
| P-02041 | 17% | S01 | — | — | 27 |
| P-02087 | 17% | S01 | BR-03 | no change | 40 |
| P-02276 | 17% | S01 | — | — | 57 |
| P-02437 | 17% | S01 | — | — | 64 |
| P-02550 | 17% | S01 | — | — | 70 |
| P-02568 | 17% | S01 | — | — | 51 |